柏克®Farabloc歷年的臨床醫學研究報告及國際醫學期刊發表
(內容來自加拿大Farabloc
Development Corporation原廠網站)
以下為歷年來醫學機構對柏克Farabloc應用於各種症狀所做的臨床研究報告，六篇中有五篇分別發表於歐美各醫學期刊。
臨床風濕期刊
Clini Rheumatol
-
針對柏克應用於纖維肌痛症候群Fibromyalgia舒緩之研究。
臨床運動醫學期刊
Clinical Journal of Sport Medicine
- 針對柏克應用於遲發性肌肉酸痛Dealyed-Onset Muscle Soreness舒緩之研究。
臨床疼痛醫學期刊
CLINICAL JOURNAL OF PAIN
-
針對柏克應用於急性與慢性幻覺痛舒緩之研究。
加拿大BC省醫學期刊
BC Medical Journal
-
針對柏克應用於"痛"舒緩之研究。
加拿大復健期刊
Canadian Journal of Rehabilitation
-
針對柏克應用於幻覺痛舒緩之研究。
德國巴哈博士
G. L. Bach (M.D.)
-
針對柏克應用於幻覺痛、風濕痛及其他多種疼痛舒緩之研究。
Efficacy of Farabloc as an analgesic in primary fibromyalgia.
Department of
Medicine/Rheumatology, University of Munich, Munich, Germany, Clin Rheumatol
臨床風濕期刊.
2007 Jan 11; PMID: 17216399
The
goal of our study was to determine the efficacy of Farabloc, an electromagnetic
shielding fabric compared to placebo fabric when worn as a nightgown, as an
analgesic in patients hospitalized with fibromyalgia. In a rheumatologic and
rehabilitation hospital, we performed a phase 1, single-blind study of patients
using Farabloc (F) or placebo (P) gowns for 8 h per night during the 20-day
hospitalization and a phase 2, single-blind crossover study of patients using
both F and P gowns randomly and alternatively switching after 10 of 21 days
hospitalization (phase 1: 42 F, mean age 49.02 years, 35 female, 7 male; 84 P,
mean age 48.08 years, 72 female, 12 males; phase 2: 25 F/P, P/F, or P/P, mean
age 44.0 years, 24 female, 1 male). The study involved randomly selected and
blinded use of hospital gown 8 h per night of either F or P fabric. The main
outcome measures were changes from admission or midpoint to discharge in
quantity of pain (QN), quality of pain (QL), and paracetamol use (PU). In phase
1, all three variables significantly favored F over P when using paired t test,
two sample t test, Mann-Whitney, and analysis of covariance tests. QN was
reduced (F = -2.03 -/+ 0.99*, P = 0.59 -/+ 0.71). QL was reduced (F = -10.64 -/+
5.69*, P = -2.54 -/+ 3.40). PU was reduced (F = 10.69 -/+ 6.68*, P = 26.12 -/+
9.37). In phase 2, comparing midpoint to discharge levels in the three variables
again favored P/F over F/P and P/P (>0.001): QN (P/F +16.00 -/+ 8.35* F/P -13.27
-/+ 11.40), QL (P/F +8.71 -/+ 4.75* F/P -6.55 -/+ 5.59), and PU (F -9.29 -/+
4.39* P -18.00 -/+ 5.27) (*p = <0.001). Patients with fibromyalgia had less pain
after sleeping in a gown made of Farabloc than with a placebo fabric. This
suggests that Farabloc, an electromagnetic shielding fabric, has analgesic
properties in fibromyalgia. Reduced pain observation is consistent with previous
studies in phantom limb pain and delayed onset muscle pain. Limitations of this
study include single blind design, small sample size, and in phase 2, a lack of
washout period and a F/F group.
The Efficacy of Farabloc, An Electromagnetic Shield, in Attenuating
Delayed-Onset Muscle Soreness
Published in the Clinical Journal of
Sport Medicine 臨床運動醫學期刊,
January 2000, Volume 10, Number 1
PMID: 10695845 [PubMed - Indexed for MEDLINE]
A
double Blind Cross-Over Study carried out by Jian Zhang M.Sc., Douglas Clement
M.D. and Jack Taunton M.D. at the Allan McGavin Sports Medicine Centre, Division
of Sports Medicine School of Human Kinetics and Department of Family Practice,
at the University of British Columbia.
Objective
To determine the effect of Farabloc, a
fabric with electromagnetic shielding properties, in attenuating the symptoms,
signs and muscular strength of delayed onset muscle soreness (DOMS) induced by
two exposures to eccentric exercise in human subjects.
Results
Repeated Measure Analysis of Variance
was carried out for each of seven variables assessing fabric, order, time and
all combinations VAS, EST, MDA, CPK, Mb, WBC and Neutral, all show highly
significant fabric effect supporting the hypothesis of a difference between
Farabloc and placebo groups.
This
analysis shows that the order of Farabloc or placebo fabric use in stage 1 and 2
produces different results. This may be caused by training or learning effect
but did not alter the overall influence of Farabloc
Conclusions
Farabloc shields high frequency
electromagnetic fields thereby may reduce cellular excitability via increased
cell membrane electric potential and reduced ionic pore activity plus
suppressing free radical formation by inhibition of iron containing enzymes
limiting the potential cascade of lipid peroxidation and inflammation in DOMS
Evidence for the Optimal Management of Acute and Chronic Phantom Pain: A
Systematic Review
Published in the CLINICAL JOURNAL OF
PAIN
臨床疼痛醫學期刊2002;
18:84-92
PMID: 11882771 [PubMed - indexed for MEDLINE]
Objectives
The objective was to examine the evidence to
determine the optimal management of phantom limb pain in the preoperative and
postoperative phase of amputations.
Conclusion
...there is some evidence suggesting consideration
of Farabloc.
Alleviation of pain with the use of Farabloc, an electromagnetic shield: A
review
Published in BC Medical Journal
加拿大BC省醫學期刊
Volume 43, Number 10, December 2000, pages 573-577
Objective
Review the research on the alleviation
of pain by Farabloc, a fabric with electromagnetic shielding properties.
Conclusion
Farabloc, an electromagnetic shielding
fabric, reduces pain in human subjects who suffer from phantom limb pain or
delayed onset muscle soreness when assessed in placebo-controlled cross-over
designed studies
The Efficacy of Farabloc In the Treatment of Phantom Limb Pain
Published in the Canadian Journal of Rehabilitation
加拿大復健期刊
Volume 6, Number 3, 1993 pp.155 --161 ISSN 0828-0827
A
clinical study undertaken by the University of British Columbia (1990 -- 1992)
Contract ordered by the British Columbia Ministry of Health.
The study was carried out by Tali A. Conine, DHSc, PT: Cecil Hershler, MD, pH,
FRCP; Stacey A Alexander, B.Sc., PT and Robert Crisp, B.Sc., PT. With the
assistance of Mr. Wayne Jones, statistical analyst, and Ms. Salima Jeraj,
research assistant. Over
60% of the patients studied reported their greatest pain relief using a Farabloc
blanket or garment.
Farabloc in the Treatment of Phantom Pain,
Rheumatic Pain and Other Painful Symptoms
A study
carried out in 1987 by Prof. G.L. Bach (M.D.)
德國巴哈博士
Formerly Professor and Chairman of Clinical Immunology and Rheumatology -Chief University of Loyola --Medical Division at Cook County Hospital, Chicago,
Illinois and the University of Loyola, Maywood, Illinois, USA
|
